Company intelligence

Celea Therapeutics

As of July 2, 2026, Celea Therapeutics has raised at least $180M in equity across 1 sourced funding round.

Clinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.

BiotechBoston, Massachusetts, USAFounded 2025Website β†—See connections β†’
Last verified Jul 31, 2026

Celea Therapeutics at a glance

As of
Equity raised
$180M[1]
Across 1 sourced roundDerived
Lead investors
RA Capital[2]
Funding round Β· July 2026
Headquarters
Boston, Massachusetts, USA[3]
  1. [1] Equity raised: Sum of the 1 sourced equity round in the funding history below (debt, tender offers and rumored rounds excluded), July 2, 2026
  2. [2] Lead investors: Celea Therapeutics, July 2, 2026
  3. [3] Headquarters: Celea Therapeutics (retrieved September 5, 2026)

What Celea Therapeutics does

Celea Therapeutics is a clinical-stage biopharmaceutical company focused on serious respiratory diseases, based in Boston.[1] Celea's lead program is deupirfenidone (LYT-100), a deuterated form of pirfenidone, one of three FDA-approved therapies for idiopathic pulmonary fibrosis.[1] The drug has Orphan Drug Designation from the FDA and the European Commission.[1] In the Phase 2b ELEVATE IPF trial, deupirfenidone showed the potential to stabilize lung function decline over at least 26 weeks as a monotherapy.[1] Participants included RA Capital Management, Leaps by Bayer and PureTech, alongside a large U.S. healthcare-focused fund and a sovereign wealth fund that were not named.[1] PureTech is also entitled to up to $190 million in aggregate milestone payments tied to sales.[1] The proceeds fund SURPASS-IPF, a head-to-head Phase 3 trial testing whether deupirfenidone is superior to pirfenidone.[1] In October 2026, imaging CRO Qureight said Celea had selected it to support the SURPASS-IPF trial.[2],[1]

Leadership

  • Sven Dethlefs, a former CEO of Teva North America, was appointed to lead the company.[3]

Celea Therapeutics profile

written 2026-10-31

Celea Therapeutics is a Boston clinical-stage biopharmaceutical company developing deupirfenidone, backed by a $180 million financing closed in July 2026.

What Celea Therapeutics does

Celea Therapeutics is a clinical-stage biopharmaceutical company based at 6 Tide Street in Boston that is dedicated to advancing transformative treatments for people with serious respiratory diseases. Its lead program is deupirfenidone, also known as LYT-100, which is in Phase 3 development as a potential new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.[1],[2],[3]

Celea Therapeutics describes deupirfenidone as a next-generation antifibrotic and a deuterated form of pirfenidone, one of the FDA-approved therapies for IPF. The company says uptake of and adherence to approved antifibrotics has historically been limited by a tradeoff between modest efficacy and tolerability, and that only about 25% of people with IPF in the U.S. had ever received treatment as of 2019.[4]

Funding

Celea Therapeutics announced the completion of a $180 million financing on July 2, 2026. The company said participants included RA Capital Management, Leaps by Bayer, and founder PureTech Health (LSE: PRTC), alongside a large, U.S.-based healthcare-focused fund and a leading sovereign wealth fund.[4]

Celea Therapeutics said the proceeds from the $180 million financing would support the planned early third-quarter 2026 initiation of the Phase 3 SURPASS-IPF trial. The company later confirmed it dosed the first patient in that trial on July 13, 2026, eleven days after the financing closed.[4],[3],[1]

Celea Therapeutics has not disclosed a valuation in the sources opened for this profile. No funding round before the July 2026 financing is named on the company's own news page, which lists PureTech Health's prior internal funding of the program before Celea was spun out as a separate company.[4],[5]

History

Celea Therapeutics was launched by PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company, as a new Founded Entity. PureTech's announcement named Sven Dethlefs, PhD, to lead Celea and said the launch reflected PureTech's model of advancing differentiated programs through focused, capital-efficient structures with seasoned leadership.[6]

PureTech Health completed a successful Phase 2b trial of deupirfenidone in December 2024, before Celea existed as a separate company, and a meeting with the U.S. Food and Drug Administration to discuss those results and the proposed Phase 3 design was expected by the end of the third quarter of 2025. PureTech said it would pursue third-party funding for Celea to advance the program through Phase 3 and potential commercialization, a plan realized by the July 2026 financing.[6],[3],[1]

Celea's leadership team was further built out following what the company calls its spin-off from PureTech Health and the closing of the $180 million financing in July 2026. The sources opened for this profile do not give an exact date for the spin-off itself.[7],[4]

People

Celea Therapeutics appointed Paul Audhya, MD, MBA, as Chief Medical Officer, the company announced on October 29, 2026. Audhya most recently served as Chief Medical Officer of KalVista Pharmaceuticals and previously held senior leadership roles at Arena Pharmaceuticals, Vertex Pharmaceuticals, Hospira and Reata Pharmaceuticals.[7]

Celea Therapeutics' other named leaders include Chief Financial Officer Vishwas (Vish) Setia, who previously served as CFO of MapLight Therapeutics and led its Series D financing and IPO after a decade in healthcare investment banking at BofA Securities; Chief Operating Officer Ronen Tamir, who held leadership roles at Pfizer, Teva Pharmaceutical Industries, GE Healthcare, Rosetta Genomics, Novartis and EMD Serono; and General Counsel David M. Stark, who previously served as Chief Legal Officer of Teva Pharmaceutical Industries.[7],[1]

Customers and partners

Celea Therapeutics is a clinical-stage company with no approved products, so it has no customers in the commercial sense. Its SURPASS-IPF trial partners include clinical investigators such as Rafael Lupercio, M.D., a pulmonologist at Shasta Critical Care Specialists in Redding, California, who dosed the first patient in the trial.[3]

Celea Therapeutics' financial backers double as strategic partners: the $180 million financing syndicate included RA Capital Management, Leaps by Bayer, founder PureTech Health, an unnamed large U.S.-based healthcare-focused fund, and an unnamed sovereign wealth fund. The company also cites support from the Pulmonary Fibrosis Foundation, whose President and CEO Scott Staszak commented on the SURPASS-IPF trial launch.[4],[3]

Competitors

Celea Therapeutics' deupirfenidone is designed to compete with existing FDA-approved antifibrotics for IPF, namely pirfenidone and nintedanib, the two approved treatments the company says have combined peak global sales exceeding $5 billion. SURPASS-IPF is designed as a head-to-head trial directly against pirfenidone rather than placebo, which the company frames as a direct competitive test against the existing standard of care.[6],[3]

Is something wrong on this page?

Company Snapshot

Celea Therapeutics is a biotech company, based in Boston, Massachusetts, USA, founded 2025.

Recent changes

  1. Jul 2, 2026Raised $180M Celea Therapeutics
  2. Jul 2, 2026New investor: Leaps by Bayer Celea Therapeutics
  3. Jul 2, 2026New investor: PureTech Health Celea Therapeutics
  4. Jul 2, 2026New investor: RA Capital Celea Therapeutics
  5. Jul 2, 2026Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug Pulse story
Earlier changes (1)
  1. Jul 2, 2026Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3 Pulse story

Funding history

1 equity event Β· newest first Β· sources dated per row
DateRoundAmountValuationLead investorsSource
Jul 2, 2026Funding round$180Mβ€”Celea Therapeutics

Equity only. β€œEquity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.

How Celea Therapeutics has been funded

On July 2, 2026, Celea announced the completion of a $180 million financing.[1] PureTech put $30 million into the round and reserved another $70 million to potentially support Celea later.[1] After the financing, PureTech holds 35.4% of Celea's fully diluted share capital.[1]

Investors

Latest Pulse

  1. Estuary Biotherapeutics Launches With $103M For Kidney Gene TherapyEstuary Biotherapeutics emerged from stealth with $103 million, including a $93 million Series A led by RA Capital, to advance gene therapies for a common inherited kidney disease.β†’
  2. The Quiet IPO Pipeline Building Beneath the Mega-DealsA wave of new S-1 filings this week -- spanning cybersecurity, biotech, medical devices and SPAC vehicles -- shows a broader IPO pipeline building beneath the mega-cap headlines like Agility Robotics and SK Hynix.β†’
  3. Biotech VCs Are Betting Big on Single Clinical TrialsCelea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.β†’
  4. The Return of the $100M+ Vertical AI RoundTwelveLabs' $100M video-AI raise and Celea Therapeutics' $180M biotech round show growth-stage investors writing nine-figure checks into narrow, vertical AI applications again, not just horizontal infrastructure plays.β†’
  5. Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis DrugCelea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.β†’
  6. Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech AppetiteScribe Therapeutics filed to raise up to $75 million in a Nasdaq IPO, becoming an early test of public-market appetite for Phase 1 biotechs -- its lead candidate, a CRISPR-based epigenetic therapy targeting PCSK9 to lower LDL cholesterol, is already in a.β†’
  7. Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.β†’

Coverage Timeline

newest first
  1. Jul 5, 2026FUNDINGBiotech VCs Are Betting Big on Single Clinical Trials$391M+ combined across 3 single-trial bets→
  2. Jul 4, 2026FUNDINGThe Return of the $100M+ Vertical AI Round$100M-$180M vertical AI rounds→
  3. Jul 2, 2026FUNDINGCelea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug$180M Series B→
  4. Jul 2, 2026FUNDINGCelea Therapeutics Raises $180M to Push Lung Drug Into Phase 3$180 million→

All Coverage

FUNDING
Biotech VCs Are Betting Big on Single Clinical Trials
Illustration for: Biotech VCs Are Betting Big on Single Clinical Trials
FUNDING$391M+ combined across 3 single-trial bets

Biotech VCs Are Betting Big on Single Clinical Trials

Celea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.

FUNDING
The Return of the $100M+ Vertical AI Round
Illustration for: The Return of the $100M+ Vertical AI Round
FUNDING$100M-$180M vertical AI rounds

The Return of the $100M+ Vertical AI Round

TwelveLabs' $100M video-AI raise and Celea Therapeutics' $180M biotech round show growth-stage investors writing nine-figure checks into narrow, vertical AI applications again, not just horizontal infrastructure plays.

FUNDING
Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug
Illustration for: Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug
FUNDING$180M Series B

Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug

Celea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.

FUNDING
Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3
Illustration for: Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3
FUNDING$180 million

Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3

PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.

Value Add Research

Related Companies

Celea Therapeutics FAQ

Where is Celea Therapeutics headquartered?

Celea Therapeutics is a clinical-stage biopharmaceutical company focused on serious respiratory diseases, based in Boston.[1]

How much has Celea Therapeutics raised?

Celea Therapeutics has raised at least $180M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $180M funding round in July 2026, reported by Celea Therapeutics. Debt financing, tender offers and secondary sales are not counted.

Who invested in Celea Therapeutics?

Lead investors in Celea Therapeutics's sourced funding rounds include RA Capital. Per round: its July 2026 funding round was led by RA Capital.

References

researched 2026-10-24
  1. Yahoo Finance
  2. news-medical.net
  3. markets.financialcontent.com
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data Β·